Page 39 - Adicet Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Bausch Health Companies (BHC) There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB – Research Report), Bausch Health Companies (BHC – Research Report) and Adicet Bio (ACET – Research Report) with bullish sentiments. Biogen (BIIB) In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Biogen, with a price target of $305.00. The company’s shares closed last Thursday at $259.00. According to TipRanks.com, Fein is a 5-star analyst with a...

Published: Apr 13, 2021 MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will lead Adicet’s research group and will further develop existing and new opportunities for the Company’s gamma delta T cell platform. “We are very excited to have Blake join Adicet, and lead our research team as we advance the clinical developm...

Editas Medicine  James Mullen takes over as CEO from Feb. 15. Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon—later snapped up by Thermo Fisher—and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo...

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress -- Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval -- -- XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020 -- -- Positive CHMP Opinion for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma Issued; European Commission Decision Expected by A...

Life Biosciences appoints Joan Mannick, MD, to lead its research and development Expert on aging will focus on R&D pipeline and clinical preparations News provided by Share this article Share this article BOSTON, Feb. 1, 2021 /PRNewswire/ -- Life Biosciences, a pioneering life sciences company targeting aging biology, announced today the appointment of Joan Mannick, MD, as Head of Research and Development. With more than 20 years of experience, Dr. Mannick will direct and manage the company's portfolio of R&D operations. "We are excited to welcome Dr. Mannick as our Head of R&D," said Mehmood...